Radiofrequency ablation of hepatocellular carcinoma

Issued: July 2003

NICE interventional procedure guidance 2
www.nice.org.uk/ipg2
1 Recommendations

1.1 Current evidence of the safety and efficacy of radiofrequency ablation (RFA) for hepatocellular carcinoma appears adequate to support use of the procedure, provided that normal arrangements are in place for consent, audit and clinical governance.

1.2 It is recommended that:

- patient selection should be carried out by a multidisciplinary team that includes a hepatobiliary surgeon
- the procedure should be monitored by CT or ultrasound.
2 The procedure

2.1 Indications

2.1.1 Hepatocellular carcinoma is one of two common malignant tumours affecting the liver. The majority of malignant liver tumours are unsuitable for surgical excision because of their number, distribution and/or the presence of residual disease elsewhere. Therefore, a number of alternative treatments have been developed, of which RFA is one.

2.2 Outline of the procedure

2.2.1 RFA is a recently developed minimally invasive technique that destroys tissue by heating. Electrodes are inserted percutaneously into the tumour and current is applied to generate local heating and destroy tissue.

2.3 Efficacy

2.3.1 There is evidence that RFA results in tumour destruction, which may be associated with higher survival rates. For more details refer to the overview (see 'Sources of evidence considered by the Committee').

2.4 Safety

2.4.1 Complications of RFA are not common, but include hepatic abscess and injury to bile ducts. The rate of complications appears lower than that with alternative treatments. Evidence suggests a mortality rate of 1% or less. For more details refer to the overview (see 'Sources of evidence considered by the Committee').

2.4.2 The specialist advisors suggested the complication rate to be 3–5%.
2.5 Other comments

2.5.1 The Committee noted that there was less evidence available about the safety and efficacy of RFA in treatment of colorectal metastases. Guidance for this indication will be postponed pending the publication of a systematic review by the Australian Medical Services Advisory Committee.
3 Further information

Sources of evidence considered by the Committee

The following source of evidence was considered by the Interventional Procedures Advisory Committee.


Information for patients

NICE has produced information on this procedure for patients and carers ('Understanding NICE guidance'). It explains the nature of the procedure and the guidance issued by NICE, and has been written with patient consent in mind.
4 About this guidance

NICE interventional procedure guidance makes recommendations on the safety and efficacy of the procedure. It does not cover whether or not the NHS should fund a procedure. Funding decisions are taken by local NHS bodies after considering the clinical effectiveness of the procedure and whether it represents value for money for the NHS. It is for healthcare professionals and people using the NHS in England, Wales, Scotland and Northern Ireland, and is endorsed by Healthcare Improvement Scotland for implementation by NHSScotland.

This guidance was developed using the NICE interventional procedure guidance process.

We have produced a summary of this guidance for patients and carers. Information about the evidence it is based on is also available.

Changes since publication

29 November 2011: minor maintenance.

Your responsibility

This guidance represents the views of NICE and was arrived at after careful consideration of the available evidence. Healthcare professionals are expected to take it fully into account when exercising their clinical judgement. This guidance does not, however, override the individual responsibility of healthcare professionals to make appropriate decisions in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

Implementation of this guidance is the responsibility of local commissioners and/or providers. Commissioners and providers are reminded that it is their responsibility to implement the guidance, in their local context, in light of their duties to avoid unlawful discrimination and to have regard to promoting equality of opportunity. Nothing in this guidance should be interpreted in a way which would be inconsistent with compliance with those duties.

Copyright

© National Institute for Health and Clinical Excellence 2003. All rights reserved. NICE copyright material can be downloaded for private research and study, and may be reproduced for
Radiofrequency ablation of hepatocellular carcinoma

educational and not-for-profit purposes. No reproduction by or for commercial organisations, or for commercial purposes, is allowed without the written permission of NICE.

Contact NICE

National Institute for Health and Clinical Excellence
Level 1A, City Tower, Piccadilly Plaza, Manchester M1 4BT

www.nice.org.uk
nice@nice.org.uk
0845 033 7780